{"url_path":"/sec/ngne/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000046-index.html","accession_number":"0001404644-26-000046","cik":"0001404644","ticker":"NGNE","issuer_name":"Neurogene Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000046-index.html","primary_entity_key":"0001404644","primary_entity_name":"Neurogene Inc."},"word_count":174,"has_tables":true,"body_markdown":"Item 7.01Regulation FD Disclosure\n\nOn June 29, 2026, Neurogene Inc. (the “Company”) issued a press release announcing positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. The Company will host a conference call and webcast today, Monday, June 29, 2026 at 8:00 a.m. Eastern Time, to discuss the data results A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Item 7.01 and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing."}